Skip to search boxSkip to navigationSkip to main content

Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: Relationship with angiotensin converting enzyme polymorphisms

  • José L. Pérez-Castrillón(corresponding author)
    ,
  • Jesús Silva
    ,
  • Isabel Justo
    ,
  • Alberto Sanz
    ,
  • Miguel Martín-Luquero
    ,
  • Rosa Igea
*Corresponding author for this work
  • Hospital Universitario Río Hortega
    ,
  • University of Valladolid
    ,
  • Pfizer, SLU
Research Output:
Contribution to journal
Article
Research
Peer-review

Abstract

Background: Many alterations in extracellular metabolism of calcium have been associated to hypertension, but the number of studies relating this disease with osteoporosis is extremely low. This study clarifies the therapeutic effect of three treatments - quinapril, quinapril + hydrochlorothiazide (HCTZ), enalapril - on bone remodeling markers, bone mineral density (BMD) in hypertensive patients, and relationship with angiotensin converting enzyme (ACE) polymorphism. Methods: This open, prospective study included 134 patients with low-to-moderate hypertension and stable BMD according to Joint National Committee criteria and 96 patients completed the study. After a washout period, patients were randomized to one of the three treatments, which they received for 1 year. Analyses of blood and urine samples and densitometric studies on lumbar spine were performed. Results: Calcium and 25-hydroxyvitamin D levels increased (9.5 ±0.3 and 9.6 ±0.3 mg/dL, P = .01 and 46 ±22 and 58 ±22 nmol/L, P = .026, respectively) in the quinapril-treated group and calcium levels increased (9.4 ±0.6 and 9.8 ±0.4 mg/dL, P = .001) in the quinapril-HCTZ-treated group. The 1, 25-dihydroxyvitamin D levels, calciuria, and calcium/creatinine ratio decreased (64 ±23 and 43 ±16 nmol/L, P = .0001;209 ±93 and 161 ±93 mg/24 h, P = .0022;0.21 ±0.09 and 0.17 ±0.11, P = .04, respectively). In the enalapril-treated group 1, 25-dihydroxyvitamin D levels (61 ±27 and 42 ±19 nmol/L, P = .0022) decreased. Only women presented a statistical significance (1.064 ±0.16 g/cm2, P = .034) between ID+II polymorphism and BMD decrease, and between DD polymorphism with less BMD under baseline conditions and a BMD increase (1.070 ±0.16 g/cm2, P = .017) after ACE inhibitor treatment. Conclusions: The ACE inhibitors have a beneficial effect on BMD and calcium metabolism alterations in hypertensive subjects. Concerning BMD response, women presenting with the II+ID polymorphism had a poor response to antihypertensive drug treatment, whereas women with the DD polymorphism responded better. This is the first study demonstrating a relationship between ACE polymorphism and BMD response and antihypertensive ACE inhibitor treatment.

Research Output Information

Output type

Research Output:
Contribution to journal
Article
Research
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 453-459 (7 pages)

Journal (Volume, Issue Number)

American Journal of Hypertension (Volume 16, Issue 6)

Publication milestones

  • Published - 01/06/2003

Publication status

Published - 01/06/2003

ISSN

0895-7061

Publication IDs

  • Scopus: 0038542890
  • PubMed: 12799093

Publication metrics

Metrics

SciVal
FWCI
0.81
SciVal
Author count
11
SciVal
Paper percentile
67
SciVal
citations
77
Scopus
citations

PlumX, opens in new tab

Citation count
77
Captures
45